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A B S T R A C T
Objectives: In this study, the commercially available AID AmpC line probe assay (LPA) was evaluated for
detection of plasmid-mediatedblaAmpC β-lactamase genes in Enterobacterales as well as chromosomal
mutations in the blaAmpC promoter/attenuator regions in Escherichia coli.
Methods: Accuracy of the AID AmpC probes was assessed using Enterobacterales clinical isolates
harbouring diverse plasmid-mediated AmpC enzymes (ACC, ACT, DHA, FOX, CMY and MOX) and E. coli
clinical isolates with mutations in the chromosomal blaAmpC promoter/attenuator regions. The diagnostic
performance of the AID AmpC LPA for blaAmpC detection directly from clinical specimens was determined
using 99 clinical urine specimens with bacterial cell counts >105CFU/mL and the results were compared
with culture-based phenotypic drug susceptibility testing (DST).
Results: Detection of blaAmpC genes in Enterobacterales clinical isolates showed 100% congruence with
phenotypic DST results. The AID AmpC LPA showed 100% speciﬁcity [95% conﬁdence interval (CI) 96–
100%] and 100% sensitivity (95% CI 75–100%) for detection of plasmid-meditated blaAmpC and E. coli
genomic blaAmpC promoter/attenuator mutations directly from clinical urine specimens. The AID AmpC
LPA detected three AmpC-producers in urine specimens with bacterial cell counts >105CFU/mL that were
missed by culture-based phenotypic DST, thereby displaying higher diagnostic sensitivity.
Conclusion: The AID AmpC LPA is an accurate, sensitive and easy-to-use test that can be readily
implemented in any diagnostic laboratory for molecular detection of blaAmpC genes in Enterobacterales.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
1. Introduction
The prevalence of multidrug-resistant Enterobacterales has
increased continuously over the past few years [1] and they are
now recognised as a common cause of severe community- and
hospital-acquired infections [2,3]. Hence, rapid detection of
resistance mechanisms that can compromise standard antibiotic
therapies, such as carbapenemases, broad-spectrum β-lactamases,
extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases,
in Enterobacterales has become of crucial importance.
In Gram-negative bacteria, AmpC production can be chromo-
somal or plasmid-mediated. Chromosomal blaAmpC genes are
constitutively expressed at low levels. In some Enterobacterales,
such as Citrobacter spp., Serratia spp. and Enterobacter spp.,
chromosomal blaAmpC expression is strongly induced by β-lactam
antibiotics. However, mutations in the promoter or attenuator
regions of the chromosomal blaAmpC gene may result in constitu-
tive overexpression of AmpC [4,5]. In addition to induction of the
blaAmpC gene, Enterobacterales can also acquire plasmid-encoded
blaAmpC genes, which are constitutively expressed [6]. The majority
of plasmid-mediated blaAmpC genes have been reported in
Escherichia coli and Klebsiella pneumoniae [7–13], although they
are also reported in other members of the Enterobacterales [10,14].
AmpC β-lactamases represent a major clinical challenge since they
can confer resistance to all β-lactam drugs, except for cefepime,
cefpirome and carbapenems [15]. Furthermore, AmpC production
in combination with porin defects may also lead to carbapenem
resistance [16]. In vitro, tazobactam can inhibit AmpC activity at
high drug concentrations. However, a recent clinical study
showed non-inferiority of the commonly used piperacillin/
tazobactam combination to carbapenems for the treatment of
AmpC-producing isolates [17]. Since carbapenem-sparing treat-
ment options can only be implemented with exact microbio-
logical results, precise identiﬁcation of β-lactamases is thus a
genuine medical need.
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Phenotypic drug susceptibility testing (DST) can detect
chromosomal AmpC overexpression and plasmid-mediated AmpC
production but is unable to distinguish the different types of
plasmid-mediated AmpC β-lactamases [18,19]. Rapid identiﬁcation
of AmpC β-lactamases is necessary for timely implementation of
hospital infection control measures and for efﬁcient epidemiologi-
cal surveillance.
This study evaluated the AID AmpC line probe assay (LPA) (AID
Autoimmun Diagnostika GmbH, Straßberg, Germany) for the
detection of blaAmpC β-lactamase genes. This assay is designed to
identify and differentiate plasmid-mediated blaAmpC genes and
point mutations in the chromosomal blaAmpC promoter/attenuator
regions responsible for AmpC overexpression in E. coli.
2. Methods
2.1. Clinical isolates and DNA fragments used for evaluation of the AID
AmpC line probe assay
A collection of 168 non-duplicate clinical Enterobacterales
isolates was used to determine the diagnostic performance of the
AID AmpC LPA. All 168 isolates had been previously phenotypically
analysed for the presence of AmpC enzymes [20]. Of the 168
clinical Enterobacterales isolates, 38 (22.6%) were found to be
AmpC β-lactamase-producers by phenotypic DST [20], and the
results were conﬁrmed by multiplex PCR [21].
For evaluation of the diagnostic performance of the LPA probes,
DNA fragments corresponding to plasmid-mediated blaAmpC
[blaFOX (1149 bp, GenBank accession no. NG_049098.1), blaMOX
(1149 bp, accession no. NG_049311.1), blaACC (1161 bp, accession
no. NG_048588.1) and blaACT-1 (1147 bp, accession no.
NG_048597.1)] as well as E. coli chromosomal blaAmpC sequences
with mutations in the promoter (bimut, –15 ln t, –15 ln tg) and
attenuator regions (mut2, del2) that were not available from
clinical Enterobacterales isolates were synthesised and cloned into
the pUC57-plasmid by Genscript Biotech. Corp. (Piscataway, NJ,
USA).
2.2. Culture and phenotypic determination of AmpC production
Retrospective analysis of antibiograms from bacteria isolated
from urine specimens (sent from secondary- or tertiary-care
hospitals) in the routine bacteriology laboratory of the Institute of
Medical Microbiology of the University of Zurich (Zurich,
Switzerland) was performed to determine the prevalence of
AmpC-producers in the Zurich metropolitan area (Supplementary
Fig. S1).
Clinical specimens were analysed for the presence of AmpC β-
lactamase-producing isolates using culture and phenotypic DST.
Brieﬂy, 10 mL of urine specimen was placed onto Columbia agar
with 5% sheep blood (bioMérieux SA, Marcy-l’Étoile, France),
chromogenic UriSelectTM4 agar (Bio-Rad Laboratories, Hercules,
CA, USA) and Columbia colistin/nalidixic acid agar with 5% sheep
blood (bioMérieux SA) and was incubated on average for 16 h.
Species-level identiﬁcation of bacteria was performed by matrix-
assisted laser desorption/ionisation time-of-ﬂight mass spectrom-
etry (MALDI-TOF/MS) (Brucker, Bremen, Germany). Antimicrobial
susceptibility to cephalosporins was determined by the disk
diffusion method using 30 mg cefoxitin disks (i2a, Montpellier,
France) on Mueller–Hinton agar plates (Becton Dickinson,
Allschwil, Switzerland) employing the interpretative criteria
recommended by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [22]. When the cefoxitin inhibition
zone diameter was <19 mm, phenotypic DST for cefoxitin was
repeated in combination with cloxacillin. Enterobacterales were
considered AmpC-producers when a 4 mm increase in the
inhibition zone diameter was observed compared with cefoxitin
alone [20].
2.3. AID AmpC line probe assay testing
The AID AmpC LPA can detect plasmid-mediated blaAmpC genes
(blaACC, blaACT, blaDHA, blaFOX, blaCMY and blaMOX) as well as
mutations in the E. coli blaAmpC promoter (–42, –32, bimut, –18/–1,
–15 ln g, –15 ln t, –15 ln tg) and attenuator regions (mut, mut2,
del1, del2) (Supplementary Fig. S2). Testing of the AID AmpC LPA
(AID Autoimmun Diagnostika GmbH) was performed following the
manufacturer’s instructions. Brieﬂy, DNA was extracted from
bacterial isolates using InstaGene Matrix (Bio-Rad, Reinach,
Switzerland). DNA was extracted from 200 mL of urine specimen
on a QIAsymphony system (QIAGEN, Hilden, Germany) with the
QIA DSP Virus/Pathogen Kit. PCR ampliﬁcation was performed with
primers speciﬁc for the blaAmpC target genes, and PCR amplicons
were hybridised to the probes immobilised on the LPA.
The AID AmpC LPA was assessed as interpretable if it showed
(i) a positive hybridisation signal with the conjugate and
ampliﬁcation control, (ii) a clear hybridisation signal with the
promoter/attenuator wild-type or mutant probes or (iii) a clear
hybridisation signal with one of the plasmidic blaAmpC probes. The
AID AmpC LPA was assessed as uninterpretable if it showed (i) no
hybridisation signal with the conjugate and ampliﬁcation control
or (ii) a weak hybridisation signal with the blaAmpC wild-type
probes.
2.4. AID AmpC line probe assay testing from clinical urine specimens
To evaluate the diagnostic performance of the AID AmpC LPA
directly from clinical specimens, ﬁrst the limit of detection of the
AID AmpC LPA from urine specimens was determined (Supple-
mentary Methods; Supplementary Fig. S3). Next, a prospective
study was performed using a set of 99 urine samples with bacterial
cell counts >105 CFU/mL from unique patients with urinary tract
infection (UTI) collected from May–October 2017 at secondary- or
tertiary-care hospitals in the Zurich metropolitan area. These 99
urine specimens were analysed in parallel by AID AmpC LPA and
phenotypic DST.
2.5. Discrepancy analysis
A 2  2 contingency table was used to display the results from
the AID AmpC LPA and culture-based phenotypic DST for the 99
urine specimens. To resolve discrepant results between pheno-
typic DST and AID AmpC LPA in three urine specimens, a 271-bp
fragment of the E. coli blaAmpC promoter/attenuator region was
ampliﬁed using primers AB1 (50-GATCGTTCTGCCGCTGTG-30) and
ampC2 (50-GGGCAGCAAATGTGGAGCAA-30) [23]. Plasmid-mediat-
ed blaAmpC genes were ampliﬁed by PCR using the primers
previously described by Pérez-Pérez and Hanson [21]. Sequences
of PCR products were then veriﬁed by Sanger sequencing. Finally,
this compiled gold standard (i.e. culture-based phenotypic DST
and Sanger sequencing) was used for evaluation of the diagnostic
performance of the AID AmpC LPA directly from urine specimens.
2.6. Ethics
The research study was conducted in accordance with the
Declaration of Helsinki and national and institutional standards.
The Act on medical research involving human subjects does not
apply to this study. This study was approved by the Ethical
Committee of the Canton of Zurich, Switzerland.
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3. Results
3.1. Diagnostic performance of the AID AmpC line probe assay
The accuracy of the AID AmpC probes was assessed using
clinical E. coli isolates with chromosomal blaAmpC promoter (–18/–
1mut, –15 ln g, –32mut and –42mut) and attenuator mutations
(mut and del2) as well as E. coli isolates harbouring blaDHA and
blaCMY genes. In addition, E. coli isolates carrying synthetic gene
constructs with plasmidic blaAmpC genes (blaACC, blaACT, blaFOX and
blaMOX) or chromosomal blaAmpC promoter (bimut, –15 ln t, –15 ln
g, –15 ln tg) and attenuator mutations (mut2 and del1) were used
for evaluation of the AID AmpC LPA. The AID AmpC LPA detected
the corresponding blaAmpC genes with 100% accuracy (Table 1).
The diagnostic performance of the AID AmpC LPA was
investigated using 168 selected clinical Enterobacterales isolates
(116 E. coli, 33 K. pneumoniae, 14 Klebsiella oxytoca and 5 Citrobacter
koseri; Table 2) including 38 AmpC-producers and 130 non-AmpC-
producers. Overall, the AID AmpC LPA exhibited excellent
performance, showing complete congruence with phenotypic
DST results (Table 2).
3.2. Phenotypic versus genotypic detection of AmpC-producing
Enterobacterales directly from clinical urine specimens
The limit of detection of the AID AmpC LPA directly from urine
specimens was a bacterial cell count of >105 CFU/mL (Supplemen-
tary Fig. S3), corresponding to the widely accepted threshold for a
relevant bacteriuria. Subsequently, 99 urine specimens above the
limit of detection were subjected to the AID AmpC LPA and
phenotypic DST. Of the 99 urine specimens, 3 (3.0%) showed a
weak hybridisation signals with the E. coli blaAmpC promoter/
attenuator wild-type probes on the AID AmpC LPA that could not
be interpreted as either ‘positive’ or ‘negative’. From these three
urine specimens, cultured E. coli isolates showed no AmpC
production as determined by phenotypic DST, which is consistent
with the hybridisation signals on the LPA (i.e. E. coli blaAmpC
promoter/attenuator wild-type; Table 3). Nevertheless, as hybrid-
isation signals on the LPA could not be initially interpreted, these
three LPAs were scored as uninterpretable and the urine samples
were subsequently excluded from the study.
In ten Enterobacterales that were phenotypically resistant to
cefoxitin (inhibition zone diameter <19 mm), the AID AmpC LPA
detected plasmid-mediated blaAmpC genes in nine isolates and
blaAmpC promoter mutations in one E. coli isolate (Tables 3 and 4).
Of 96 Enterobacterales isolates tested, 83 (86.5%) were phenotypi-
cally susceptible to cefoxitin and all tested negative by the AID
AmpC LPA. In three urine specimens, AmpC-producers were
identiﬁed by the AID AmpC LPA but the cultured E. coli isolates
were phenotypically susceptible to cefoxitin (inhibition zone
diameter 19 mm) (Table 3). PCR ampliﬁcation and sequencing
directly from the cultured isolates conﬁrmed the presence of a
plasmid-mediated DHA blaAmpC gene in one isolate and a
chromosomal blaAmpC promoter mutation (mut –18/–1) in the
other two E. coli isolates (Table 4). This resulted in 100% speciﬁcity
[95% conﬁdence interval (CI) 96–100%] and 100% sensitivity (95% CI
75–100%) for blaAmpC detection directly from urine specimens by
the AID AmpC LPA.
4. Discussion
This study investigated the diagnostic performance of the new,
commercially available AID AmpC LPA targeting plasmid-mediated
blaAmpC genes (blaACC, blaACT, blaDHA, blaFOX, blaCMY and blaMOX) as
well as mutations in the chromosomal E. coli blaAmpC promoter/
attenuator regions. To our knowledge, the AID AmpC LPA is
Table 1
Analysis of AmpC-producing Enterobacterales isolates or synthetic blaAmpC genes using the AID AmpC line probe assay.
Atten, attenuator; prom, promoter; syn, synthetic DNA; wt, wild-type.
aThe genotype of all Escherichia coli isolates has been independently veriﬁed by multiplex PCR or sequencing.
bWild-type (wt) probes highlighted in grey.
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Table 2
Analysis of 168 clinical Enterobacterales isolates using the AID AmpC line probe assay.
Atten, attenuator; ESBL, extended-spectrum β-lactamase; prom, promoter; wt, wild-type.
aAmpC production has been independently veriﬁed in all strains by phenotypic drug susceptibility testing, PCR ampliﬁcation and sequencing.
bWild-type (wt) probes displayed in grey.
cNine AmpC-producing E. coli isolates additionally produced an ESBL; one isolate additionally produced an ESBL and a carbapenemase.
dThe AmpC-producing Klebsiella pneumoniae isolate additionally produced an ESBL and a carbapenemase.
Table 4
Detection of blaAmpC genes directly from clinical urine specimens (n = 13) by the AID AmpC line probe assay (LPA).
Culture and phenotypic DST AID AmpC LPA resulta
Species identiﬁcation Cell count (CFU/mL) FOX inhibition zone diameter (<19 mm)
Klebsiella pneumoniae >105 + DHA
Citrobacter freundii >105 + CMY
C. freundii >105 + CMY
Hafnia alvei >105 + ACC
Enterobacter cloacae complex >105 + ACT
Morganella morganii >105 + DHA
Escherichia coli >105 + –42 and –18/–1 promoter mut
K. pneumoniae >105 + ACT
Klebsiella oxytoca >105 + ACT
C. freundii >105 + CMY
E. coli >105 FOX-susceptible DHA
E. coli >105 FOX-susceptible 18/1 promoter mut
E. coli >105 FOX-susceptible 18/1 promoter mut
DST, drug susceptibility testing; FOX, cefoxitin.
a The AID AmpC LPA results have been independently veriﬁed by PCR ampliﬁcation and Sanger sequencing.
Table 3
Characterisation of AmpC-producing Enterobacterales in clinical urine specimens (n = 99 with bacterial cell count >105 CFU/mL) by culture-based phenotypic drug
susceptibility testing (DST) and the AID AmpC line probe assay (LPA).
AID AmpC LPA Culture and phenotypic DST, PCR ampliﬁcation and sequencing
No AmpC-producers detected AmpC-producers detected
No blaAmpC detected 86a 0
blaAmpC detected 0 13b
a Three AID AmpC LPAs showed weak hybridisation signals with the Escherichia coli blaAmpC promoter/attenuator wild-type probes and were determined as non-AmpC-
producers by culture-based phenotypic DST.
b A plasmid-mediated blaAmpC gene was identiﬁed in one E. coli isolate, and an E. coli blaAmpC promoter mutation (promoter 18/1mut) was conﬁrmed in two E. coli
isolates by PCR ampliﬁcation and Sanger sequencing.
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currently the only commercially available assay enabling broad
molecular identiﬁcation of blaAmpC genes in Enterobacterales.
Overall, the AID AmpC LPA exhibited excellent diagnostic
performance with clinical Enterobacterales isolates. All blaAmpC
genes were correctly identiﬁed in phenotypic AmpC-producers,
and all non-AmpC-producers were correctly identiﬁed, resulting in
100% congruence with phenotypic DST results. The concomitant
presence of ESBLs or carbapenemases in some Enterobacterales
isolates did not interfere with blaAmpC detection by the AID AmpC
LPA. This represents a competitive advantage over culture-based
phenotypic DST that is often unable to identify multiple β-
lactamases on the basis of minimum inhibitory concentration
(MIC) patterns [24,25].
Moreover, the AID AmpC LPA can be used for rapid detection of
AmpC-producers directly from clinical urine specimens (with
bacterial cell counts >105 CFU/mL). The AID AmpC LPA is faster and
easier to perform than culture-based phenotypic DST and provided
accurate molecular detection and differentiation of blaAmpC genes
(chromosomal versus plasmid-mediated AmpC). Furthermore, it
was more sensitive than culture-based detection of AmpC β-
lactamases. However, reliable AmpC detection by the AID AmpC
LPA required bacterial cell counts >105 CFU/mL. Thus, pre-
screening of urine specimens is advisable in order to reduce
unnecessary molecular testing. To this end, ﬂow cytometers such
as the UF-4000 (Sysmex Europe GmbH, Norderstedt, Germany) or
other bacterial cell counting techniques that enable rapid
determination of bacterial cell numbers in urine specimens could
be employed prior to AID AmpC LPA molecular testing.
Several cases of nosocomial outbreaks caused by Enterobacter-
ales with plasmid-encoded AmpC β-lactamases have been
reported in recent years [9,26,27]. In a prospective surveillance
study conducted in Switzerland in 2012, the prevalence of AmpC-
producers was found to be 0.16% in Enterobacterales and 0.2% in E.
coli [28]. In the current study, a marked increase in AmpC-
producers was observed among Enterobacterales causing UTIs
(4%). This observation is alarming given the strict policy of
antibiotic prescription in Switzerland [29]. Enterobacterales
producing plasmid-mediated AmpC β-lactamases raise special
concern because of the high rate of clinical failure among patients
treated with standard antibiotic regimens [30–32]. Moreover,
plasmid-encoded blaAmpC genes in Enterobacterales are often
associated with additional resistance determinants [33–35],
further limiting therapeutic options. AmpC-producers can be
detected by culture-based phenotypic DST. Costs for urine culture
and phenotypic DST are low (less than s12 per bacterial isolate)
but they have a turnaround time of 2 days. In contrast,
implementation of molecular methods enables more rapid
identiﬁcation (<1 working day) and precise characterisation of
AmpC β-lactamases. Molecular assays for detection of plasmid-
mediated blaAmpC genes, such as the multiplex PCR developed by
Péréz-Péréz and Hanson [21], are now widely used in diagnostic
practice. Moreover, a PCR reverse hybridisation assay for detection
of ACT, ACC-1, DHA, MOX, FOX and CMY-2-type β-lactamase genes
has been recently developed [36]. However, these assays cannot
detect mutations in the E. coli blaAmpC promoter/attenuator
regions, requiring time-consuming PCR ampliﬁcation and DNA
sequencing. Moreover, commercial assays offer some advantages
compared with molecular tests developed ‘in-house’. First,
manufacturing of the assays is strictly controlled and standardised
to ensure test accuracy and reproducibility. Chemicals and kit
reagents have a speciﬁc shelf-life and a lot number for diagnostic
laboratory use, and laboratory protocols have been extensively
validated ensuring consistency in the performance of the assay.
Also, whole-genome sequencing (WGS) has been successfully
employed for the detection of genes and/or mutations that result in
phenotypic drug resistance in Enterobacterales [37]. However,
WGS is still costly and slow (more than s100 per bacterial isolate;
turnaround time of 2–3 working days) and requires expensive
equipment (sequencers, library preparation kits, etc.) and highly
trained staff (bioinformaticians, etc.). In contrast, LPAs are cheap
(less than s25), fast (<1 working day), easy to use and can readily
be employed in every diagnostic laboratory with a PCR machine
available, enabling molecular blaAmpC detection also in resource-
limited settings.
The most signiﬁcant limitation of this study is the low prevalence
of some AmpC types (e.g. ACC, ACT, FOX and MOX) in our region.
Therefore, the reliability in detecting these rarely occurring blaAmpC
genes by the AID AmpC LPA needs to be assessed by sequencing of
the respective blaAmpC genes. Another limitation of this study is that
the majority of blaAmpC genes were detected in E. coli. Although
blaAmpC genes in four Klebsiella spp. (from one culture isolate and
three urine specimens) and three Citrobacter freundii (from urine
specimens) were correctly identiﬁed, and 45 Klebsiella spp. and 7
Citrobacter spp. without plasmidic blaAmpC genes did not show
hybridisation signals on the AID AmpC LPA, analysis of a greater
number of non-E. coli strains carrying blaAmpC genes is required to
corroborate the analytical performances of this method.
In conclusion, the AID AmpC LPA is a rapid and accurate
molecular assay that allows precise characterisation of plasmid-
mediated and chromosomal blaAmpC genes in Enterobacterales. It
can easily be implemented in diagnostic laboratories and be used
for early detection of antimicrobial resistance, to guide antibiotic
therapy and to monitor resistance epidemiology.
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